Let’s get to it quickly because we’ve got some key details to go over.
Starting at $3.31 on March 8th, my last breakout idea reached a high of $4.54 the next day, resulting in an approximate 37%, 2-day increase.
During after-hours on the 8th, the profile surged to $5.20, an approximate 57% increase from its opening price that same day.
Now, tonight at 7:00PM EST, I’ve got a new Biopharma profile (Nasdaq) to bring to your full attention.
Flying under Wall Street’s radar at the moment, this company has an impressive intellectual property (IP) portfolio, including key patents on its technology and methods for treating neurodegenerative and infectious diseases.
Parkinson’s disease is a neurological condition characterized by involuntary or uncontrolled movements, including tremors, rigidity, and impaired coordination and balance.
The projected value of the global Parkinson’s disease treatment market is estimated to exceed $12Bn by 2030.
With a potential treatment on the horizon, companies in this field may have a promising opportunity to secure a significant share of the market.
As I mentioned above, Wall Street hasn’t picked up on the potential this company is producing at the moment which is why we’re putting together a detailed report to help you be better prepared going into Monday’s opening bell.
Here’s a couple key details to soak in ahead of tonight’s report:
No. 1: As per Yahoo Finance, the reported number of shares available for trading suggests that this is a low float profile. Such a small float size makes it highly susceptible to sudden market volatility.
No. 2: A recent FDA ruling has allowed this company to proceed with an important clinical trial without delay. This favorable decision is a significant boost for the firm.
No. 3: This company has formed robust partnerships with renowned research institutions, including the National Institutes of Health (NIH) and other reputable organizations focused on Parkinson’s disease research.
Hang tight for right now. The complete report arrives tonight at 7:00PM EST.